On July 1, 2026, Wyoming’s Stem Cell Freedom Act took effect, adding another state to the patchwork of laws governing non-FDA-approved stem cell therapy. For physicians tracking this landscape, the practical questions are what actually changed, what stayed the same, and what none of these laws do. This update covers the July 1 change, the current five-state framework, and the federal rules that remain unchanged.
TLDR: On July 1, 2026, Wyoming’s Stem Cell Freedom Act (Senate File 48), codified at W.S. 33-26-202(b), took effect, allowing Wyoming physicians to administer non-FDA-approved autologous mesenchymal stem cell therapy with a licensing-discipline shield. Florida, Utah, California, and Nevada laws remained in place and unchanged. A critical point holds across all five states: these laws govern administering therapy or disclosure obligations, not tissue banking, which is a separate preservation activity. No state law changes federal regulation, and no adipose-derived product is FDA-approved for disease treatment. Banking preserves a patient’s own tissue under 21 CFR Part 1271; it is not a treatment and does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease or condition. No adipose-derived stem cell product currently has FDA approval for disease treatment. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
State law in this area changes frequently, and accurate tracking matters for compliance. The sections below summarize the July 2026 status and link to the evergreen state-law map for ongoing reference.
What Changed on July 1, 2026: Wyoming SF 48 Is Now in Effect
The change on July 1, 2026, was the effective date of Wyoming’s Stem Cell Freedom Act, Senate File 48, codified at W.S. 33-26-202(b). The law passed the Wyoming Legislature unanimously and was signed in March 2026. It allows a Wyoming physician to recommend and administer stem cell therapy using a patient’s own cells that is not FDA-approved, and it provides a shield against state licensing discipline for physicians who do so responsibly, subject to informed consent and medical-standard requirements.
Two features distinguish the Wyoming law. First, it is specifically limited to autologous mesenchymal stem cells, meaning cells derived from a patient’s own fat, bone marrow, or connective tissue, which is a different scope from states focused on perinatal cells. Second, it directs the Wyoming Board of Medicine to maintain a registry of physicians qualified to perform such therapy. The detailed provider overview of the Wyoming Stem Cell Freedom Act covers the obligations. Critically, like every law discussed here, SF 48 governs administering therapy, not banking.
The Five-State Framework as of July 2026
As of July 2026, five states have notable stem cell laws, and they differ substantially in scope and approach. Wyoming, effective July 1, 2026, covers autologous mesenchymal stem cell therapy. Florida, under Section 458.3245 effective July 1, 2025, permits physicians to administer non-FDA-approved stem cell therapy within three named areas, orthopedics, wound care, and pain management, with disclosure and consent obligations, as detailed in the Florida physician checklist. Utah, under Utah Code Section 58-1-512, requires specific disclosure and consent for non-FDA-approved stem cell therapy and focuses on placental and perinatal cells and human cells and tissues, summarized in the Utah disclosure law overview.
California and Nevada round out the framework. California’s Business and Professions Code Section 684, in effect since 2017, requires physicians performing non-FDA-approved stem cell therapy to post and provide a specified notice, and it expressly excludes therapies meeting the federal minimal-manipulation criteria, as the California disclosure law overview explains. Nevada, under its Chapter 629 framework adopted in 2023, takes a permissive approach to non-FDA-approved biologics and, effective January 1, 2026, requires certain primary care providers to inform patients about stem cell storage and donation options. The evergreen state-law map tracks these in detail.
State-by-State Status Table: July 2026
The table summarizes the five-state framework as of July 2026.
| State | Statute | What it governs | Scope | Status |
|---|---|---|---|---|
| Wyoming | W.S. 33-26-202(b) (SF 48) | Administering non-FDA-approved therapy; physician licensing shield | Autologous MSCs (fat, marrow, connective tissue) | Effective July 1, 2026 |
| Florida | Section 458.3245 (SB 1768) | Administering non-FDA-approved therapy; disclosure and consent | Orthopedics, wound care, pain management | Effective July 1, 2025; unchanged |
| Utah | Section 58-1-512 | Disclosure and consent for non-FDA-approved therapy | Placental and perinatal cells; HCT/Ps | 2024, amended 2026; unchanged |
| California | B&P Section 684 | Required patient notice; excludes minimal-manipulation HCT/Ps | Non-FDA-approved HCT/P therapy | In effect since 2017; unchanged |
| Nevada | NRS Chapter 629 | Permits non-FDA-approved biologics; provider storage disclosure | Nonembryonic cells | 2023; disclosure rule effective Jan 1, 2026 |
Across every row, the law concerns administering therapy or disclosure obligations, not tissue banking.
What Has Not Changed at the Federal Level
No state law changes federal regulation, and that is the most important point for any physician. The FDA continues to regulate human cells and tissues under 21 CFR Part 1271, and no adipose-derived product is FDA-approved for disease treatment. A state law that shields a physician from state licensing discipline does not alter federal law or FDA enforcement authority, and the tension between these state laws and federal regulation is well documented.
For banking specifically, the federal framework is what governs. Banking intact adipose tissue is handled under 21 CFR Part 1271, and it is a preservation activity distinct from the therapy administration these state laws address. A physician should not read any state therapy law as authorizing or regulating banking, because banking and administering therapy are different activities under different parts of the regulatory framework. This separation also matters for enforcement. The FDA has consistently treated administering non-FDA-approved cell products as distinct from preserving a patient’s own tissue, and a state shield against licensing discipline does nothing to change how the FDA approaches products that fall within its jurisdiction. For banking, the relevant question remains compliance with the federal tissue framework, not the contours of any state therapy law.
States to Watch for 2027 Legislative Sessions
The trend of state-level stem cell legislation is likely to continue, and several states may consider bills in their 2027 sessions. The pattern so far has moved between two models: disclosure-focused laws, like those in California and Utah, and access-focused laws that shield physicians, like those in Florida and Wyoming. Physicians in states without current legislation should monitor their own legislatures, because this area is active.
Rather than predict specific outcomes, the practical approach is to track developments through a maintained resource and reassess compliance whenever a relevant law changes. The state-law map is updated as the landscape shifts. Whatever new laws emerge, the distinction between administering therapy and banking is likely to remain, and banking will continue to be governed by the federal tissue framework. Physicians can also expect continued attention from federal regulators and from professional bodies, which have generally urged caution about non-FDA-approved cell therapies regardless of state law. The prudent posture is to treat state authorization as narrow, to document carefully, and to keep banking clearly separated from any therapy a practice may or may not offer.
Physician Action Checklist: July 2026 Compliance Review
A condensed compliance review for July 2026:
- Confirm which state’s law applies to the practice, and whether it is a disclosure-focused or access-focused law, using the correct statutory citation.
- For Wyoming, note that SF 48 is codified at W.S. 33-26-202(b) and took effect July 1, 2026, covering autologous mesenchymal stem cell therapy.
- Recognize that all five state laws govern administering therapy or disclosure, not banking, which remains a separate preservation activity.
- Maintain that no state law alters federal regulation under 21 CFR Part 1271, and that no adipose-derived product is FDA-approved for disease treatment.
- For banking specifically, confirm the banking partner operates under 21 CFR Part 1271 and keep banking documentation separate from any therapy records.
Frequently Asked Questions
What exactly changed on July 1, 2026?
Wyoming’s Stem Cell Freedom Act (Senate File 48), codified at W.S. 33-26-202(b), took effect. It allows Wyoming physicians to administer non-FDA-approved autologous mesenchymal stem cell therapy with a shield against state licensing discipline, subject to consent and medical-standard requirements.
Do any of these state laws authorize adipose tissue banking?
No. All five state laws govern administering non-FDA-approved therapy or disclosure obligations, not tissue banking. Banking is a separate preservation activity governed by the federal framework under 21 CFR Part 1271.
Does a state law override FDA regulation?
No. No state law changes federal regulation or FDA enforcement authority. The FDA continues to regulate human cells and tissues under 21 CFR Part 1271, and no adipose-derived product is FDA-approved for disease treatment.
How is Wyoming’s law different from Florida’s?
Wyoming’s law covers autologous mesenchymal stem cells from a patient’s own tissue and shields physicians from licensing discipline, while Florida’s law permits administration within three named areas, orthopedics, wound care, and pain management, with disclosure and consent obligations. Both govern administering therapy, not banking.
How is adipose tissue banking regulated?
Banked adipose tissue is handled under 21 CFR Part 1271, the federal framework governing screening, processing, and storage of human cells and tissues, regardless of state therapy laws.
Key Takeaways
For physicians tracking the state landscape, July 2026 added Wyoming to a five-state framework without changing the fundamentals. Wyoming’s Stem Cell Freedom Act, codified at W.S. 33-26-202(b), took effect July 1, 2026, allowing physicians to administer non-FDA-approved autologous mesenchymal stem cell therapy with a licensing shield, while Florida, Utah, California, and Nevada laws remained unchanged. The decisive point across all five states is that these laws govern administering therapy or disclosure, not tissue banking, which is a separate preservation activity. No state law alters federal regulation under 21 CFR Part 1271, and no adipose-derived product is FDA-approved for disease treatment. Above all, banking adipose tissue is a preservation service for potential future use; it is not a treatment, and it does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians reviewing their compliance posture can consult the state-law map and contact the team to discuss how banking fits a practice.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review is required before publication. Please consult your physician before making any decisions about treatment or research participation.
